Supporters of the bill say it will give treatment opportunities to patients who already have explored every other option.
“Thousands of terminally ill Americans will finally have hope, and the fighting chance, and I think it’s going to better than a chance, that they will be cured, they will be helped, and be able to be with their families for a long time, or maybe just for a longer time,” said President Trump, according to The Hill.
Most Democrats opposed the bill, saying it is dangerous for patients to take drugs that have not been cleared by the FDA.
“FDA oversight of access to experimental treatments exists for a reason — it protects patients from potential snake oil salesmen or from experimental treatments that might do more harm than good,” said Rep. Frank Pallone, D-N.J.
More articles on leadership and management:
Dr. Anthony Tersigni: Innovative care models are new catalysts to transforming healthcare
Kindred, Massachusetts General Hospital to lay off 152 workers
10 thoughts on the healthcare business
At Becker's 4th Annual CEO + CFO Roundtable, taking place November 2–5 in Chicago, more than 1,500 hospital and health system executives tackle decisions that determine whether organizations thrive or merely survive: protecting margins under cost pressure, choosing where to grow, renegotiating payer relationships, stabilizing the workforce and proving real ROI on technology. This is where leaders work through them together, face-to-face. Apply for complimentary registration now.